Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC — VULCANIZE-II  

Squamous Cell Carcinoma of the Vulva Clinical Trial

Official title: Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For Locally Advanced Vulvar Carcinoma

Status Recruiting

Clinical Trial Summary

A phase 2 randomised controlled trial will be performed in which the efficacy and safety of standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for six weeks) and experimental treatment (NACT; consisting of carboplatin and paclitaxel in a 3-weekly scheme) will be compared in 98 patients with LAVC, registered from eight national medical centres.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Squamous Cell Carcinoma of the Vulva
• Vulvar Neoplasms

• NCT number: NCT05905315
• Study type: Interventional
• Source: The Netherlands Cancer Institute
• Contact: Frederic Amant, Prof.
• Phone: 0031205129111
• Email: f.amant@nki.nl
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2024
• Completion date: September 1, 2029